Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Six-year study finds bone health maintained in children on VOXZOGO
BioMarin (Nasdaq: BMRN) presented new data at the Pediatric Endocrine Society’s 2026 Annual Meeting, showing that long-term treatment with VOXZOGO (vosoritide) in children with achondroplasia improved arm span Z-scores, maintained arm span-to-height proportionality, and preserved bone mineral density while increasing bone mineral content. Children who started treatment after age 5 showed significant height gains of 10.60 cm at six years and 13.59 cm at eight years compared to untreated cohorts. Additionally, the company expects topline Phase 3 results for hypochondroplasia in the first half of 2026, with studies already showing statistically significant improvements in total body minus head BMD and BMC in hypochondroplasia patients.